INT304045

Context Info Confidence 0.51 First Reported 2010 Last Reported 2010 Negated 1 Speculated 0 Reported most in Body Documents 2 Total Number 4 Disease Relevance 4.12 Pain Relevance 1.40

lipid binding (PTEN) cell proliferation (PTEN) cytosol (PTEN) plasma membrane (PTEN) nucleus (PTEN) enzyme binding (PTEN)

PTEN (Homo sapiens)

Pain Link Frequency Relevance Heat methotrexate 159 99.64 rheumatoid arthritis 162 92.36 Arthritis 102 90.80 spinal inflammation 93 90.32 antagonist 34 88.16 Etanercept 12 87.12 Adalimumab 15 85.92 headache 3 75.52 Inflammation 57 50.44 Infliximab 21 48.32

Disease Link Frequency Relevance Heat Microsatellite Instability 47 99.84 Infection 18 99.46 Endometrial Cancer 153 99.32 Latent Tuberculosis 18 99.26 Hyperplasia 18 92.96 Rheumatoid Arthritis 162 92.36 Seronegative Spondarthritis 93 90.80 Low Back Pain 99 90.32 Lymphatic System Cancer 12 79.16 Disease 61 77.68

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

On the other hand, identical PTEN mutations have been detected in MSI-negative endometrial hyperplasia with coexisting MSI-positive endometrioid endometrial carcinomas.

Neg (negative) Transcription (detected) of PTEN associated with microsatellite instability and endometrial cancer

1) Confidence 0.51 Published 2010 Journal Obstetrics and Gynecology International Section Body Doc Link PMC2846683 Disease Relevance 1.56 Pain Relevance 0

One case of bone TB infection was reported in a patient receiving GLM 50 mg + MTX in the GO-BEFORE trial.

Transcription (receiving) of GLM associated with latent tuberculosis, methotrexate and infection

2) Confidence 0.09 Published 2010 Journal Core evidence Section Body Doc Link PMC2899784 Disease Relevance 1.73 Pain Relevance 0.70

This review describes the development and molecular characterization of GLM, and the preclinical data and early clinical trial experience with this novel anti-TNF-?

Transcription (describes) of GLM

3) Confidence 0.09 Published 2010 Journal Core evidence Section Body Doc Link PMC2899784 Disease Relevance 0.40 Pain Relevance 0.21

Antibodies to GLM were detected in seven (6.5%) of the 107 GLM-treated patients (five patients in the GLM 50 mg dose groups and two patients in the GLM 100 mg dose groups) at week 48 of the phase II trial in patients with RA.20 None of the patients who were positive for antibodies to GLM experienced a severe injection site reaction or serious adverse event, and none discontinued study agent because of lack of efficacy.20 Rates of anti-GLM antibody detection reported for the phase III trials were similar to or less than those observed for other anti-TNF monoclonal antibodies in clinical trials and ranged from 3.7% (GO-AFTER) to 4.6% (GO-REVEAL) of GLM-treated patients.25,26 Outcomes summary

Transcription (detected) of GLM associated with rheumatoid arthritis

4) Confidence 0.07 Published 2010 Journal Core evidence Section Body Doc Link PMC2899784 Disease Relevance 0.44 Pain Relevance 0.50

General Comments

This test has worked.